Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SU5416 in Advanced Soft Tissue Sarcoma
NCT00005862Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2000
- Primary completion
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semaxanib in soft tissue sarcoma (STS) and gastrointestinal stromal tumor (GIST), sponsored by National Cancer Institute. Primary endpoints: Response Rate at 1 year, Response Duration at 1 year and 1 more. Started Oct 2000; status: completed.
02
Drugs
semaxanib
03
Conditions
soft tissue sarcoma (STS)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00005862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005862.